
Headache and Migraine
Latest News
Latest Videos

CME Content
More News

Neurology News Network. for the week ending December 7, 2024. [WATCH TIME: 4 minutes]

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

Catch up on any of the neurology news headlines you may have missed over the course of November 2024, compiled all into one place by the NeurologyLive® team.

Early data from the pilot RELIEV-CM trial showed significant reductions in headache and migraine days, with 56% of patients showing a 50% reduction in symptoms at 4 weeks, and 100% at 12 weeks.

The assistant professor of neurology at the Icahn School of Medicine at Mount Sinai provided an overview of a session on exercise and migraine presented at the 2024 Scottsdale Headache Symposium. [WATCH TIME: 5 minutes]

The pediatric neurologist at Duke Health and chief executive officer at Theranica talked about a remote electrical neuromodulation wearable that showed promising results for the treatment and prevention of migraine in pediatric patients. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending November 23, 2024. [WATCH TIME: 4 minutes]

The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]

The findings suggest that future phase 3 trials should explore the duration of pain relief and headache recurrence, with the goal of developing structured treatment guidelines for PTH.

Nerivio, a nondrug option for acute migraine attacks and prevention of migraine with or without aura, has been FDA-approved for several years in adolescents aged 12 and older as well as adults.

Catch up on any of the neurology news headlines you may have missed over the course of October 2024, compiled all into one place by the NeurologyLive® team.

STS101 showed promising results in previous trials, with significant pain relief and minimal adverse events reported, reinforcing its potential as a viable treatment for patients with migraine.

In the study, both migraine and gestational diabetes mellitus independently increase the risk of premature major cardiovascular and cerebrovascular events, with the highest risk observed among those with both conditions.

Over months 4 through 6, 69.1% of participants on erenumab 140 mg, and 60.3% of the erenumab 70 mg group achieved MOH remission compared with 52.6% of those on placebo

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on medication overuse headaches.

Catch up on any of the neurology news headlines you may have missed over the course of September 2024, compiled all into one place by the NeurologyLive® team.

Michelle Bravo, MD, an assistant professor of clinical neurology at the University of Miami, provided commentary on a rare case report of a subdural hematoma linked to spontaneous intracranial hypotension caused by a refractory CSF leak.

Over half of the patients (56.7%) discontinued at least one class of acute migraine medication within 12 months post-erenumab initiation.

The phase 2 study, expected to include 575 patients with acute migraine, will use percentage of participants with freedom from pain and freedom from the most bothersome symptom as the coprimary end points.

Transition to college life poses unique challenges for students living with migraine, and a comprehensive checklist helps ensure they are prepared for this critical phase.

Nina Riggins, MD, PhD, FAAN, FAHS, UCNS Diplomate, highlighted the essential role of advocacy in advancing neurological care, particularly in improving the transition process for pediatric patients with migraine to adult care.

Stewart Tepper, MD, Vice President at the New England Institute for Neurology and Headache in Stamford, Connecticut, provided commentary on a wide-scale analysis of nearly 5000 patients testing the effects of rimegepant.

Treatment with Lu AG09222 as a migraine preventive was safe, with common adverse events that included COVID-19, nasopharyngitis, and fatigue.

Across 4 trials with over 4800 patients, rimegepant demonstrated superior pain and symptom relief 2 hours post-dose, with fewer requiring rescue medication.

CT-132, a digital therapy, targets brain hypersensitivity and provided non-pharmacological treatment, showing promise for integration into migraine management.